Fundraising Fox

Epilepsy GTx

9 employees on LinkedIn · 5 known investors

EpilepsyGTx is a preclinical-stage biotech developing gene therapies for focal refractory epilepsy (FRE), with the aim of making patients seizure free.

BiotechDigital Health

Investors · 5

AlbionVCLondon
Moonstone Venture CapitalMilan
UCL Technology FundLondon · $320K – $9M
XGEN VentureMilan
British Business BankreportedSheffield

Funding

SEC filings, press & company announcements

$33M disclosed across 1 of 2 rounds · 2024–2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

EpilepsyGTx secures $33m to progress FRE therapy through Phase I/IIa trialsclinicaltrialsarena.com · Dec 2025EpilepsyGTx’s $33m Series A brings hope for 'life changing' focal refractory epilepsy treatment - 10 - 12 - 2025 - UCLBuclb.com · Dec 2025Advising EpilepsyGTx on its US$33 million Series A financingtaylorwessing.com · Dec 2025Gene therapy for severe epilepsy moves forward with EpilepsyGTx’s €28 million funding | EU-Startupseu-startups.com · Dec 2025EpilepsyGTx Raises $33 Million Series A to Develop Single Dose Gene Therapy for Focal Refractory Epilepsybusinesswire.com · Dec 2025EpilepsyGTx Raises $10M in Seed Fundingfinsmes.com · Jun 2024

Frequently asked questions

What does Epilepsy GTx do?
EpilepsyGTx is a preclinical-stage biotech developing gene therapies for focal refractory epilepsy (FRE), with the aim of making patients seizure free.
Who are Epilepsy GTx's investors?
Epilepsy GTx's investors include AlbionVC, Moonstone Venture Capital, UCL Technology Fund, XGEN Venture, British Business Bank.
How much funding has Epilepsy GTx raised?
Epilepsy GTx has disclosed $33M raised across 1 of its 2 known rounds.